114 related articles for article (PubMed ID: 12756017)
1. The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythaemia.
Johansson P; Andréasson B; Safai-Kutti S; Wennström L; Palmqvist L; Ricksten A; Lindstedt G; Kutti J
Eur J Haematol; 2003 Jun; 70(6):358-62. PubMed ID: 12756017
[TBL] [Abstract][Full Text] [Related]
2. Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia.
Johansson P; Ricksten A; Wennström L; Palmqvist L; Kutti J; Andréasson B
Br J Haematol; 2003 Nov; 123(3):513-6. PubMed ID: 14617016
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Martini M; Teofili L; Larocca LM
Methods Mol Med; 2006; 125():265-73. PubMed ID: 16502591
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia.
Teofili L; Martini M; Luongo M; Di Mario A; Leone G; De Stefano V; Larocca LM
J Clin Oncol; 2002 Oct; 20(20):4249-54. PubMed ID: 12377969
[TBL] [Abstract][Full Text] [Related]
5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
6. Plasma erythropoietin in essential thrombocythaemia: at diagnosis and in response to myelosuppressive treatment.
Andréasson B; Lindstedt G; Kutti J
Leuk Lymphoma; 2000 Jun; 38(1-2):113-20. PubMed ID: 10811453
[TBL] [Abstract][Full Text] [Related]
7. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
[TBL] [Abstract][Full Text] [Related]
8. Oxygen affinity is decreased in patients with polycythaemia vera and essential thrombocythaemia.
Johansson P; Brudin G; Nilsson B; Andréasson B
Scand J Clin Lab Invest; 2004; 64(1):71-5. PubMed ID: 15025431
[TBL] [Abstract][Full Text] [Related]
9. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.
Griesshammer M; Klippel S; Strunck E; Temerinac S; Mohr U; Heimpel H; Pahl HL
Ann Hematol; 2004 Jun; 83(6):364-70. PubMed ID: 15034760
[TBL] [Abstract][Full Text] [Related]
10. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin.
Liu E; Jelinek J; Pastore YD; Guan Y; Prchal JF; Prchal JT
Blood; 2003 Apr; 101(8):3294-301. PubMed ID: 12515724
[TBL] [Abstract][Full Text] [Related]
11. The relation between plasma thrombopoietin and erythropoietin concentrations in polycythaemia vera and essential thrombocythaemia.
Andréasson B; Lindstedt G; Stockelberg D; Wadenvik H; Kutti J
Leuk Lymphoma; 2001 May; 41(5-6):579-84. PubMed ID: 11378575
[TBL] [Abstract][Full Text] [Related]
12. Instability of PRV-1 mRNA: a factor to be considered in PRV-1 quantification for the diagnosis of polycythemia vera.
Jelinek J; Jedlickova K; Guan Y; Prchal JT
Haematologica; 2004 Jun; 89(6):749-51. PubMed ID: 15194544
[TBL] [Abstract][Full Text] [Related]
13. The polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders.
Bock O; Serinsöz E; Neusch M; Schlué J; Kreipe H
Br J Haematol; 2003 Nov; 123(3):472-4. PubMed ID: 14617008
[TBL] [Abstract][Full Text] [Related]
14. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
15. JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia.
Melis S; Vellinga S; Zachée P; Sierens AC; De Schouwer PJ
Acta Clin Belg; 2009; 64(5):429-33. PubMed ID: 19999391
[TBL] [Abstract][Full Text] [Related]
16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
17. Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia.
Carneskog J; Kutti J; Wadenvik H; Lundberg PA; Lindstedt G
Eur J Haematol; 1998 May; 60(5):278-82. PubMed ID: 9654156
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.
Johansson P; Andréasson B
Clin Lab Haematol; 2006 Aug; 28(4):233-6. PubMed ID: 16898960
[TBL] [Abstract][Full Text] [Related]
19. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
Steimle C; Lehmann U; Temerinac S; Goerttler PS; Kreipe H; Meinhardt G; Heimpel H; Pahl HL
Ann Hematol; 2007 Apr; 86(4):239-44. PubMed ID: 17256145
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.
Tefferi A; Lasho TL; Wolanskyj AP; Mesa RA
Blood; 2004 May; 103(9):3547-8. PubMed ID: 14701686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
